About Modis Therapeutics
Modis Therapeutics is a Healthcare company based in Oakland (United States) founded in 2016, and was acquired by Zogenix in August 2019. Therapies for rare genetic mitochondrial diseases are developed. Modis Therapeutics has raised $30 million across 1 funding round from investors including Zogenix, Orbimed and F-Prime Capital. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
Modis Therapeutics was founded in 2016 in Oakland, United States. Focus is placed on providing therapies for rare genetic diseases, particularly Thymidine kinase 2 deficiency, which causes mitochondrial dysfunction and impaired cellular energy production. Deoxynucleoside combination therapy is being developed to address mitochondrial DNA depletion disorders and restore cellular function in affected patients. Operations center on biotechnology research in the rare disease sector.
- Headquarters Oakland, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website modistx.com
- Social LinkedIn
- Acquired by Zogenix (Aug 2019)
Funding Insights of Modis Therapeutics
Modis Therapeutics has successfully raised a total of $30M through 1 strategic funding round. The most recent funding activity was a Series A round of $30 million completed in October 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $30M
- Total Rounds 1
- Last Round Series A — $30M
- First Round $30M
(Oct 2018)
- Investors Count 4
All 1 funding rounds of Modis Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2018 | $30M | Series A | – | F-Prime Capital, Orbimed |
5 investors in total: 5 institutional.
Investors in Modis Therapeutics
Modis Therapeutics has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Zogenix, Orbimed and F-Prime Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Aceras Biomedical is focused on healthcare investment for medical innovations. | acerasbio.com | |||
Early- to growth-stage startups are targeted for venture capital investments. | oup.vc | Bala Cynwyd, United States | ||
Drug delivery systems for CNS disorders and pain are developed. | 2006 | zogenix.com | Emeryville, United States |
Investor details for Modis Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Modis Therapeutics
820 people are tracked at Modis Therapeutics (331 in leadership, 489 in team).
| Name | Role | Group |
|---|---|---|
Milena Iwańska | Senior Strategic Sourcing Partner At Randstad Sourceright On Behalf Of UCB | Leadership |
Catrinel Galateanu | Vp, Global Patient Community Head Immunology | Leadership |
Jean-Luc Fleurial | Executive Vice President & Chief Human Resources Officer | Leadership |
Sandrine Dufour | Executive Vice President & Chief Financial Officer | Leadership |
Sathish Kumar | Head Of Digital Technology - Patient Supply, Corporate Functions & ERP | Leadership |
Frédéric Septon | Learning & Development Partner | Leadership |
Agathe Maury - le Breton | Global Access Insights & Strategic Pricing HEAD | Leadership |
Nassim Haddad | Head Of IT Artificial Intelligence (senior Director) | Leadership |
Lisa Walsh | Rheumatology Franchise Head | Leadership |
Baran Ufuktepe | Global Rheumatology Medical Community Head | Leadership |
Taco van Tiel | Head UCB USA | Leadership |
Serkan Oray | Vice President, Head Of Devices, Artwork & Packaging | Leadership |
Federico Chinni | General Manager | Leadership |
Guendalina van Gyseghem | Director, Medical Devices Program Lead At UCB | Leadership |
Magali Courtin | Head Of External Research Opportunities | Leadership |
Tonya Adams | US Head-diversity, Equity And Inclusion | Leadership |
Paul Kusters | Head Strategic Operations | Leadership |
Quentin Hamouch | Head Of Patient Supply Digital Transformation | Leadership |
Baldur Magnusson | Executive Director - Head Late Development Statistics | Leadership |
Edwin Erckens | Chief Digital Technology Officer | Leadership |
800 more people are available in the full profile.
Complete people profiles for Modis Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Modis Therapeutics
3 dated milestones of Modis Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Modis Therapeutics is founded.
- Funding First funding round of $30.0M.
- Exit Acquired by Zogenix.
Competitors of Modis Therapeutics
Modis Therapeutics has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of Modis Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Modis Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Modis Therapeutics
Complete news archive for Modis Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Modis Therapeutics
Modis Therapeutics was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Modis Therapeutics is headquartered in Oakland, United States. It is registered at Oakland, California, United States.
Modis Therapeutics is a funded company, having raised a total of $30M across 1 funding round to date. The company's 1st funding round was a Series A of $30M, raised on Oct 2018.
Modis Therapeutics was founded in 2016 in Oakland, United States. Focus is placed on providing therapies for rare genetic diseases, particularly Thymidine kinase 2 deficiency, which causes mitochondrial dysfunction and impaired cellular energy production. Deoxynucleoside combination therapy is being developed to address mitochondrial DNA depletion disorders and restore cellular function in affected patients. Operations center on biotechnology research in the rare disease sector.
Modis Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
Modis Therapeutics has 5 investors. Key investors include Zogenix, Orbimed, F-Prime Capital, Aceras Biomedical, and Osage University Partners.
Yes. Modis Therapeutics was acquired by Zogenix in August 2019.